reviving the cryopreserved day 32 hesc-derived photoreceptor progenitors

Revitalizing Sight: Stem Cell Therapy for Retinal Degeneration

Inherited retinal diseases and age-related macular degeneration lead to photoreceptor cell loss and eventual blindness. The retinal photoreceptor is the outer segment layer of the retina comprised of specialized cells responsible for phototransduction (i.e., conversion of light to neuronal signals). The rod and cone photoreceptor cells are adjacent to the retinal pigmented layer (RPE)1. Photoreceptor cell replacement therapy to compensate the cell loss has been an emerging and developing therapeutic approach. Embryonic stem cells (ESCs)2,3,4, induced pluripotent stem cells (iPSCs)-derived RPE cells, and retinal progenitor cells (RPCs)4,5,6,7,8 were used to restore the damaged photoreceptor cells. Sub-retinal space, a confined space between the retina and the RPE, is an attractive location to deposit these cells to replace damaged photoreceptor cells, RPE, and Mueller cells due to its vicinity9,10,11.
Gene and cell therapies have been utilizing the sub-retinal space for regenerative medicine for various retinal diseases in pre-clinical studies. This includes the delivery of functional copies of the gene or gene editing tools in the form of either anti-sense oligonucleotide therapy12,13 or CRISPR/Cas9 or base editing via adeno-associated virus (AAV) based strategy14,15,16, implantation of materials (e.g., RPE sheet, retinal prosthetics17,18,19) and differentiated stem cell-derived retinal organoids20,21,22 to treat retinal and RPE-related diseases. Clinical trials using hESC-RPE31 in the sub-retinal space to treat RPE65-associated Leber congenital amaurosis (LCA)23,24, CNGA3-linked achromatopsia25, MERTK-associated retinitis pigmentosa26, choroideremia27,28,29,30 have been proven to be an effective approach. Direct injection of cells to the vicinity of the damaged area greatly improves the chance of cell settlement at the appropriate region, synaptic integration, and eventual visual improvement.
Even though sub-retinal injection in human and large-eyed models (i.e., pig32,33,34,35, rabbit36,37,38,39,40, and non-human primate41,42,43) has been&#160;established, such injection in the murine model is still challenging due to the constrain of the eyeball size and enormous lens occupying the mouse eye44,45,46. However, genetically modified models are only readily available in small animals and not in large animals (i.e., rabbits and non-human primates), therefore sub-retinal injection in mice draws attention to investigate novel therapeutic approaches in retinal genetic disorders. Three major approaches are being used to deliver cells or AAVs into the sub-retinal space, namely the trans-corneal route, trans-scleral route, and the pars plana route (See Figure 2). Trans-corneal and trans-scleral routes are associated with cataract formation, synechiae, choroidal bleeding, and reflux from the injection site11,44,45,47,48,49. We adopted the pars plana approach as a direct visualization of the injection process, and the injection site can be achieved in real-time under the microscope.
We recently described a method that can differentiate human embryonic stem cells (hESCs) into photoreceptor progenitors under xenofree, chemically defined conditions using recombinant human retina-specific laminin isoform LN523. Since LN523 was found to be present in the retina, we hypothesized that the extracellular matrix niche of the human retina could be recapitulated in vitro and thereby support photoreceptor differentiation from the hESCs36. Single-cell transcriptomic analysis showed that photoreceptor progenitors co-expressing cone-rod homeobox and recoverin were generated after 32 days. A retinal degeneration 10 (rd10) mutant mouse model that mimics autosomal human retinitis pigmentosa was used to evaluate the efficacy of the day 32 hESC-derived photoreceptor progenitors in-vivo. The hESC-derived photoreceptor progenitor cells were injected into the sub-retinal space of rd10 mice at P20, where photoceptor dysfunction and degeneration are ongoing36. Here, we describe a detailed protocol for the preparation of the post-cryopreserved hESC-derived photoreceptor progenitors and delivery into the sub-retinal space of rd10 mice. This method can also be used to administer AAVs, cell suspensions, peptides, or chemicals into the sub-retinal space in mice.

Author Spotlight: Advancing Vision Restoration - Stem Cell-Based Therapy for Retinal Diseases 

Sub-Retinal Delivery of Human Embryonic Stem Cell Derived Photoreceptor Progenitors in rd10 Mice

My research focuses on the development of stem cell based therapy for advanced stages of retinal diseases that cause photoreceptor degeneration. The goal of our research is to replace the loss of photoreceptors in patients with clinically safe and functional photoreceptor progenitors with the aim of improving their visual acuity or even restoring their vision. The main preclinical model is mice, but their small sized eyeball make it challenging to inject materials, especially under the retina.Developing the skill to perform successful subretinal injections requires patience and perseverance. We have successfully developed a laminin base for the receptor differentiation method that is able to generate photoreceptor progenitors in 32 days. The subretinal transplantations of this photoreceptor progenitors cell suspensions in the rodents resulted in synaptic connectivity between the holes and graft in the eyes.This has led to partial visual restoration. Our approach is simple, the right visualization helps the surgeon handle the needle to the area of interest.

Watch this Scientific Journal Video about Reviving the Cryopreserved Day 32 hESC-Derived Photoreceptor Progenitors at JoVE.com

Reviving the Cryopreserved Day 32 hESC-Derived Photoreceptor Progenitors  

Begin by placing PRDM in a water bath set at 37 degrees Celsius. Remove a cryovial containing day 32 hESC-derived photoreceptor progenitor cells from liquid nitrogen, and keep it on dry ice. Then thaw the cryovial in a water bath at 37 degrees Celsius for three to five minutes.Re-suspend the cells in one milliliter of PRDM. Centrifuge them at 130G for four minutes After removing the supernatant, re-suspend the pellet in one milliliter of PRDM. To count the cells, take 10 microliters of the cell suspension and mix with 0.2%trypan blue, following the manufacturer's instructions.Pipette the cell mixture into the cell counting chamber slide, and determine the cell number and viability using an automated cell counter. If cell viability is above 70%centrifuge the remaining cell suspension at 130G for four minutes. Remove the supernatant and re-suspend the cell pellet in PRDM for transplantation.Using a 10 microliter pipette tip, re-suspend cell clumps in the microfuge tube until no clumps are visible. Load the suspension into a 33-gauge injection syringe and confirm the extrusion of cell solution through the needle.

reviving-cryopreserved-day-32-hesc-derived-photoreceptor

Research

JoVE Journal

Medicine

40 Görüntüleme.  Singapore Eye Research Institute. PRDM'yi 37 santigrat dereceye ayarlanmış bir su banyosuna yerleştirerek başlayın. 32. gün hESC'den türetilmiş fotoreseptör progenitör hücrelerini içeren bir kriyoviyal sıvı nitrojenden çıkarın ve kuru buz üzerinde tutun. Daha sonra kriyoviyal 37 santigrat derecede bir su banyosunda üç ila beş dakika çözdürün.Hücreleri bir mililitre PRDM'de tekrar süspanse edin. Dört dakika boyunca 130G'de santrifüjleyin Süpernatanı çıkardıktan sonra, peleti bir mililit...